Abstract
Osteoarthritis is the most common joint disease, causing damage to cartilage and surrounding tissues and potentially leading to varying degrees of disability. The disease is characterized by pain, stiffness, and loss of function. Osteoarthritis is classified as primary and secondary. The cause of primary (or idiopathic) osteoarthritis is unknown (primary osteoarthritis accounts for the vast majority of cases). Secondary osteoarthritis may be caused by another disease or disorder, such as infection, congenital joint malformation, trauma, metabolic disorders, rheumatoid arthritis, and others. The main goals of treatment include relief of pain, preservation of joint flexibility, and optimization of joint function. Currently used conservative treatment methods are mainly aimed at reducing pain and improving the patient’s quality of life; however, they do not eliminate the underlying cause of the disease and, accordingly, are not capable of completely halting the degradation of hyaline cartilage. Attempts at joint-preserving surgery in cases of involvement of one of the knee joint compartments, such as corrective osteotomy, can significantly improve treatment outcomes but tend to delay rather than prevent the need for joint arthroplasty. Therefore, the development of treatment methods that enable joint preservation and restoration of cartilage and subchondral bone defects remains highly relevant. At present, the search for such methods is focused on the use of orthobiologic products. This article addresses the application of these approaches in the treatment of knee joint conditions. A detailed description of the composition and mechanisms of action of two orthobiologic products of greatest interest to practicing clinicians—platelet-rich plasma and stromal vascular fraction—is presented. The results of preclinical and clinical studies demonstrating the ability of these products to reduce inflammation, alleviate pain, and remarkably improve the function of the affected joint are provided. Thus, scientific studies confirm the therapeutic efficacy of orthobiologic products, the use of which opens new prospects for joint-preserving treatment of patients with osteoarthritis.

This publication has 146 references indexed in Scilit: